Volume : 7, Issue : 4, April - 2018

SCRUTINIZING CKD ASSOCIATED SECONDARY HYPERPARATHYROID DOSSIER

Ayesha Habeeb, Hafsa Sania, Maryam Shaik, Umair Wahedi, Syed Amer

Abstract :

<p class="MsoNormal" style="text-align:justify"><span style="font-size:12.0pt;&#10;line-height:115%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">The kidney:improving global outcome guideline recommended that screening of renal hyperparathyroidism(<span style="color:black;background:white">rHPT)</span> should be considered during CKD stage 3.<span style="color:black;background:&#10;white">Renal hyperparathyroidism (rHPT)or secondary hyperparathyroidism is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D.</span>A 55 yearsold male patient presented with swelling in the neck associated with difficulty in speaking and sleeping, Reduced appetite(since 15days),Anasarca(since 15days),Shortness of eath(since 15days),Nausea, Vomiting(1 episode before hospitalization), Associated with 2 cm thyroid nodule and with comorbidities (Chronic Kidney Disease(CKD) , Hypertension(HTN) and Cardiovascular Disease(CVD).Patients with rHPT have high risk of developing cardiovascular and bone diseases, This case study shows <span style="mso-spacerun:yes">&nbsp;</span>that there is a need in improving therapeutic strategies and Patient&rsquo;s medical compliance, which makes a critical component in improving outcome and patients quality of life.<o:p></o:p></span></p>